Halotestin and Tamoxifen Interaction

Avoid
Mechanism-based 64% confidence

Halotestin and Tamoxifen have a potentially harmful interaction with 64% confidence. Both Halotestin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

Halotestin

Oral Anabolic Steroid | Extreme Strength & Aggression

Fluoxymesterone exerts its effects primarily through exceptionally strong binding to the androgen receptor (AR), driven by its 9-alpha-fluoro and 11-beta-hydroxyl structural modifications that dramatically enhance receptor affinity beyond that of testosterone or DHT. Despite its extreme androgenic potency, it does not convert to estrogen via the aromatase enzyme, and its direct anabolic effect on skeletal muscle tissue is disproportionately low relative to its androgenic rating, likely due to rapid inactivation in muscle tissue.

Half-life: ~9.5 hours Typical dose: 10-20 mg/day anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Tamoxifen

Selective Estrogen Receptor Modulator | PCT & Breast Cancer Treatment

Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling.

Half-life: ~5-7 days Typical dose: 20-40mg oral daily pct
cyp3a4estrogen receptor anticoagulantcarcinogenic riskhepatotoxicpct agent
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (Halotestin, Tamoxifen). Monitor accordingly.
2x 2 hepatotoxic compounds (Halotestin, Tamoxifen). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Halotestin, Tamoxifen). Monitor accordingly.

Frequently Asked Questions

Can I take Halotestin with Tamoxifen?

Combining Halotestin with Tamoxifen is not recommended. Both Halotestin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Halotestin and Tamoxifen safe together?

This combination carries significant risk. Both Halotestin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Halotestin and Tamoxifen?

Both Halotestin and Tamoxifen carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Halotestin and Tamoxifen?

Halotestin has a half-life of ~9.5 hours and Tamoxifen has a half-life of ~5-7 days. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Halotestin vs Tamoxifen

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.